Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

### New issue announcement, application for quotation of additional securities and agreement

Introdu 04/03/13		8, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12,
	<u> </u>	
СНА	HAPMANS LIMITED  N 4 000 012 386  e (the entity) give ASX the following information.  Part 1 - All issues  I must complete the relevant sections (attach sheets if there is not enough space).  +*Class of *securities issued or to be issued  Number of *securities issued or to be issued (if known) or maximum number which may be issued  Principal terms of the *securities (e.g. if options, exercise price and expiry date; if  Ordinary fully paid shares	
ABN		
34 0	00 012 386	
We (	the entity) give ASX the followin	g information.
		sh sheets if there is not enough space).
1		Ordinary Shares
2	to be issued (if known) or maximum number which may	135,703,062 Ordinary Shares (New Shares)
3	+securities (e.g. if options,	Ordinary fully paid shares

conversion)

Appendix 3B Page 1 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment	
	• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	\$0.005 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	To fund general working capital
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	31 May 2018
6c	Number of *securities issued without security holder approval under rule 7.1	135,703,062 Ordinary Shares

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6е	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of *securities issued under an exception in rule 7.2	135,703,062
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	LR7.1 - 55,602,702 LR7.1A - 39,151,801
_	+Legue dates	a Dagambar and
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	24 December 2018
	Cross reference: item 33 of Appendix 3B.	

04/03/2013 Appendix 3B Page 3

Number

+Class

<sup>+</sup> See chapter 19 for defined terms.

8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	407,109,186	Fully paid Ordinary Shares
	Name and the of all	Number	+Class
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	87,304,000	Options exercisable on payment of \$0.015 on or before 30 November 2021
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)		
Part	2 - Pro rata issue		
11	Is security holder approval required?	No	
12	Is the issue renounceable or non-renounceable?	Non-renounceable	
13	Ratio in which the *securities will be offered	1 New Share for every as at the Record Date	2 existing shares held
14	<sup>+</sup> Class of <sup>+</sup> securities to which the	Ordinary Shares	
	offer relates		
15	<sup>+</sup> Record date to determine entitlements	3 December 2018	
16	Will holdings on different	N/A	
	registers (or subregisters) be aggregated for calculating entitlements?		
	Doligy for deciding antitlements	Emptional antida	
17	Policy for deciding entitlements in relation to fractions	to the nearest whole i	its will be rounded up number

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	No action has been taken to permit the offer of New Shares in any jurisdiction other than to investors in Australia and New Zealand.
	Cross references rate j.j.	
19	Closing date for receipt of acceptances or renunciations	5.00pm (EST) on 17 December 2018
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	6 December 2018
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	28 November 2018
	B	[37/4
28	Date rights trading will begin (if applicable)	N/A
20	Date rights trading will end (if	N/A
29	applicable)	11//1

o4/o3/2013 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B	
New issue and	nouncement

30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Issue date	24 December 2018
	3 - Quotation of securities of an are of the complete this section if you are of	
34	Type of *securities (tick one)	
(a)	*Securities described in Par	rt 1
(b)	All other +securities	
	-	end of the escrowed period, partly paid securities that become fully paid, hen restriction ends, securities issued on expiry or conversion of convertible
Entitio	es that have ticked box 34(a)	
Addit	ional securities forming a ne	w class of securities
Tick to docume	indicate you are providing the informo	ation or
35	1 1	y securities, the names of the 20 largest holders of the the number and percentage of additional *securities
36	1 1	ty securities, a distribution schedule of the additional number of holders in the categories

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

	100,001 and over		
37	A copy of any trust deed for t	the additional <sup>+</sup> securities	
Entiti	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the <sup>+</sup> securities in clause 38)	Number	+Class

04/03/2013 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>†</sup>quotation of the <sup>†</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	111	28 November 2018 Date:
0	(Company secretary)	

Print name: Peter Dykes

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital					
Step 1: Calculate "A", the base figure from which the placement capacity is calculated					
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	securities on issue 12 months before the				
Add the following:					
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	1,434,530,535				
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval	1,258,149,511				
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period	0				
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>					
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	0				
"A"	3,915,180,131				

<sup>+</sup> See chapter 19 for defined terms.

"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	587,277,019
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
<b>Insert</b> number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	31,250,000
<ul> <li>Under an exception in rule 7.2</li> </ul>	
• Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	31,250,000
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining
"A" x 0.15	587,277,019
Note: number must be same as shown in Step 2	
Subtract "C"	31,250,000
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	556,027,019
	With 1 for 10 share consolidation:

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
3,915,180	0,131			
0.10				
Note: this	s value	e canno	ot be cl	hanged
391,518,0	013			
placen	ment	сара	city u	ınder rule
)				

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	391,518,013
Note: number must be same as shown in Step 2	
Subtract "E"	0
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	391,518,013
	With 1 for 10 share consolidation:
	39,151,801
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.